Latest Cancer Screening News

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.

Cleo Diagnostics unveils a pioneering blood test for early ovarian cancer detection, boasting superior accuracy to existing methods and targeting a significant U.S. market opportunity.

INOVIQ Limited has revealed promising data for its EXO-OC™ ovarian cancer screening test, demonstrating exceptional accuracy and flawless detection of early-stage cancers. This innovation could transform early diagnosis and treatment outcomes for women worldwide.

TruScreen Group Limited has successfully raised NZ$2.35 million through a share placement, attracting new institutional investors from Asia, while launching a discounted share purchase plan for existing shareholders.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Ordinary Shares Group Limited has announced a combined share purchase plan and placement to raise approximately NZD 1.78 million, aiming to accelerate its international expansion and cervical cancer screening initiatives.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

TruScreen Group Limited has announced a NZ$3 million capital raise to fund strategic growth initiatives across Asia and Africa, alongside repaying existing debt. The raise includes a placement and share purchase plan with free attaching options, signaling confidence in its expanding cervical cancer screening programs.